Medical trials are currently being conducted at Alivation—this is your chance to help science and medicine. Study-related exams, tests and medication will be provided at no cost, and you may be compensated for your time.

Review the open research studies below and apply for the one(s) you qualify for. Bookmark this page and check back often, as studies are often updated and we’re always recruiting qualified candidates. Check out our list of studies or contact us with any questions. Participation in all research is voluntary and not everyone may qualify. If you are interested in learning how you can assist in scientific research, or if you’d like to participate in a study for a condition not listed, please call 402.476.6060, option 4.

If you would like to submit research study ideas, or if you have any questions about studies, please send an email to research@alivation.com. 

CURRENT PHARMACEUTICAL RESEARCH TRIALS:
  • Phase 2/3 study evaluating AXS-05 (bupropion hydrochloride and dextromethorphan hydrobromide monohydrate) for individuals with treatment-resistant depression
  • Duration of the study is 3 months, consisting of 10 visits to the clinic
  • Must be currently experiencing moderate to severe symptoms of depression
  • History of inadequate response to an antidepressant
  • Compensation for your time and travel is offered
    1. Phase 3 study evaluating Cariprazine as an adjunct to an antidepressant for patients diagnosed with Major Depressive Disorder or who are experiencing symptoms of depression
    2. Duration of the study is 2 months, consisting of 7 visits to the clinic
    3. Must be currently experiencing moderate to severe symptoms of depression
    4. Must be currently on an antidepressant and having an inadequate response to the treatment OR had an inadequate response to an antidepressant during the current depressive episode (not exceeding over 18 months ago)
    5. Compensation for your time and travel is offered
    1. Phase 3 study evaluating Escitalopram in children and adolescents with Generalized Anxiety Disorder
    2. Duration of the study is 10 weeks, consisting of 8 visits to the clinic

3. Must be experiencing anxiety symptoms that interfere with home, school, or social life

  • Phase 3 clinical study of Adjunctive Molindone Hydrochloride ER for the treatment of Impulsive aggression in pediatric patients with ADHD.
  • Duration of the study is 13 weeks, consisting of 7 visits.
  • Currently on a monotherapy treatment for ADHD.
  • BMI less than 99th.
  • Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
  • Compensation for your time and travel is offered.
    1. Phase 3 clinical study of Adjunctive Molindone Hydrochloride ER for the treatment of Impulsive aggression in adolescent patients with ADHD.
    2. Duration of the study is 2 months, consisting of 8 visits.
    3. Currently on a monotherapy treatment for ADHD.
    4. BMI is more than 25th and less than 99th percentile for age and gender.
    5. Subject’s parent(s) or legally authorized representative (LAR) must be able to provide informed consent and comply with study requirements.
    6. Compensation for your time and travel is offered.
    1. Phase 3 clinical study of Centanafadine Sustained-release tablets in Adults diagnosed with ADHD or experiencing symptoms of ADHD
    2. Duration of the study is 11 weeks, consisting of 9 visits to the clinic.
    3. Currently experiencing symptoms of ADHD that are interfering with school, work, or relationships, or homelife.
    4. BMI has to be between 18-40.
    5. Compensation for your time and travel is offered.
    1. Non-interventional study examining the real-life effectiveness of Trintellix in patients with major depressive disorder
    2. Looking for individuals about to start Trintellix (they cannot already be taking it)
    1. Phase 4 study evaluating Valbenazine (Ingrezza) for the treatment of Tardive Dyskinesia
    2. Duration of the study is 5 months, consisting of 7 visits to the clinic
    3. Must be experiencing uncontrollable movements or have been diagnosed with Tardive Dyskinesia
    4. Compensation for your time and travel is offered
    1. Phase 3 study evaluating Sage-217 in adults with major depressive disorder
    2. Duration of the study is 1 year
    3. Must be currently experiencing moderate to severe symptoms of depression
    4. Compensation for your time and travel is offered
    1. Phase 2/3 study evaluating TEV-50717 (Deutetrabenazine) for the treatment of Tourette Syndrome in Children and Adolescents
    2. Duration of the study is 14 weeks, consisting of 13 visits to the clinic
    3. Must be experiencing motor and/or vocal tics that cause distress or impairment with work, school, or social function
    4. Compensation for your time and travel is offered
        1. Phase 3 study evaluating TEV-50717 (Deutetrabenzaine) for the treatment of dyskinesia in cerebral palsy in children and adolescents
        2. Duration of the study is 17 weeks, consisting of 14 visits to the clinic
        3. Must have involuntary movements (dyskinesia) with chorea as the predominant movement problem (will be assessed at the screening visit)
        4. Must be able to swallow study medication
        5. Must have dyskinesia as the predominant movement disorder
  1. Non-interventional study for adults 19 and older
  2. Must have a diagnosis of Schizophrenia and about to start one of four atypical long acting injectables – Abilify Maintena, Aristada, Invega Sustenna, or Risperdal Consta
  1. Phase 3b study evaluating Abilify MyCite in adults with schizophrenia
  2. Duration of the study is 8 months, consisting of 9 visits to the clinic
  • Must possess a smartphone and willing to download the Abilify MyCite app
  1. Must be currently taking an oral atypical antipsychotic medication for 6 months or longer
  2. Must have had an inpatient hospitalization for schizophrenia within the last 4 years
CURRENT TMS RESEARCH TRIALS:
        1. Randomized clinical study of deep transcranial magnetic stimulation (dTMS) for PTSD
        2. Duration of the study is 9 weeks, consisting of 14 visits to the clinic
        3. Must have symptoms of PTSD that cause distress and impairment in at least one area of life (ex: work, school, home, social)
        4. Cannot have significant hearing loss, seizures, severe headaches, or any unstable physical disease
        5. Compensation for your time and travel is offered
Upcoming Studies

Our dedicated research staff is certified to conduct clinical trials according to Good Clinical Practices (GCP), adhering to all written standard operating procedures (SOPs) and HIPPA regulations.